Stevanato Group (STVN) has released an update.
Stevanato Group reported a modest 2% revenue increase to €277.9 million for Q3 2024, driven by strong demand in the Biopharmaceutical and Diagnostic Solutions segment, despite challenges in their Engineering segment. The company is adjusting its earnings expectations due to higher costs and inefficiencies linked to new U.S. operations and destocking issues. While maintaining revenue guidance, Stevanato is focused on long-term growth, backed by investments in high-value solutions.
For further insights into STVN stock, check out TipRanks’ Stock Analysis page.
